Indian start-up to launch tests for rare cancer
Advertisement
Kolkata: A Chennai-based personalised medicine start-up is all set to launch advanced tests for precise identification of three rare cancers, a company official said.
Swagene, one of the winners at Empresario 2016 — IIT-Kharagpur’s annual global business model competition, has developed tests for sarcomas (soft tissue cancers) such as rhabdomyosarcoma, synovial sarcoma and Ewing’s sarcoma (bone cancer) which shall be launched in February, the official informed.
“There is a market need for diagnostics of these cancers as it is very difficult to distinguish between these three.
“The market is not satisfying this particular need. We will launch the tests in early February,” Sooraj Ratnakumar, founder of the nine-month-old start-up, told IANS here.
Swagene, which finds the right therapy for patients based on genetic analysis, looks at three broad areas: infertility, cardiology and oncology.
“We look at specific disease-markers and diagnose and advise the patient and their doctors on how to proceed with therapy. For example, what therapies will work for them, which will give them severe side-effects and how to avoid those side-effects and what will not work for them,” said Ratnakumar, a molecular biologist from Cambridge University, who also spearheads the R&D at Swagene.
Ratnakumar and his team of four intend to bring advanced diagnostics to the market and make them accessible and affordable to the public.
“We go meet doctors and convince them about the tests we do… 50 percent of the tests are completely novel in this geography — for example, in infertility we identify who are the poor responders in IVF and how to overcome the poor response,” said Ratnakumar.
The tests can be ordered online anywhere in India.
Swagene, one of the winners at Empresario 2016 — IIT-Kharagpur’s annual global business model competition, has developed tests for sarcomas (soft tissue cancers) such as rhabdomyosarcoma, synovial sarcoma and Ewing’s sarcoma (bone cancer) which shall be launched in February, the official informed.
“There is a market need for diagnostics of these cancers as it is very difficult to distinguish between these three.
“The market is not satisfying this particular need. We will launch the tests in early February,” Sooraj Ratnakumar, founder of the nine-month-old start-up, told IANS here.
Swagene, which finds the right therapy for patients based on genetic analysis, looks at three broad areas: infertility, cardiology and oncology.
“We look at specific disease-markers and diagnose and advise the patient and their doctors on how to proceed with therapy. For example, what therapies will work for them, which will give them severe side-effects and how to avoid those side-effects and what will not work for them,” said Ratnakumar, a molecular biologist from Cambridge University, who also spearheads the R&D at Swagene.
Ratnakumar and his team of four intend to bring advanced diagnostics to the market and make them accessible and affordable to the public.
“We go meet doctors and convince them about the tests we do… 50 percent of the tests are completely novel in this geography — for example, in infertility we identify who are the poor responders in IVF and how to overcome the poor response,” said Ratnakumar.
The tests can be ordered online anywhere in India.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.